Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09EXD
|
||||
Former ID |
DAP000382
|
||||
Drug Name |
Rituximab
|
||||
Synonyms |
MAbThera (TN); Rituxan (TN)
|
||||
Drug Type |
Antibody
|
||||
Therapeutic Class |
Anticancer Agents
|
||||
Company |
Roche
|
||||
Formula |
C6416H9874N1688O1987S44
|
||||
CAS Number |
CAS 174722-31-7
|
||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
L01XC02
|
||||
Drug Resistance Mutation (DRM) | |||||
DRM | DRM Info | ||||
Target and Pathway | |||||
Target(s) | B-lymphocyte antigen CD20 | Target Info | [535660], [536968] | ||
KEGG Pathway | Hematopoietic cell lineage | ||||
References | |||||
Ref 536940 | Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008;68(17):2445-68. doi: 10.2165/0003495-200868170-00004. | ||||
Ref 541860 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.